Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Helland, Åslaug ^a,b,c   Anglesio, Michael S ^b,d,f   George, Joshy ^b,e   Cowin, Prue A ^b   Johnstone, Cameron N ^b   House, Colin M ^b   Sheppard, Karen E ^b   Etemadmoghadam, Dariush ^b   Melnyk, Nataliya ^f   Rustgi, Anil K ^g   Phillips, Wayne A ^b   Johnsen, Hilde ^a   Holm, Ruth ^a   Kristensen, Gunnar B ^a   Birrer, Michael J ^l   Pearson, Richard B ^b,e   Børresen Dale, Anne Lise ^a,c   Huntsman, David G ^d,f   deFazio, Anna ^h,i   Creighton, Chad J ^j   Smyth, Gordon K ^k   Bowtell, David D L ^b,e   more..

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h WESTMEAD HOSPITAL   (Australia)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

^k WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^l HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP A2 PROTEIN; DNA BINDING PROTEIN; LIN28B PROTEIN, HUMAN; MICRORNA; MIRNLET7 MICRORNA, HUMAN; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN;

ALLELE; ARTICLE; CANCER GENETICS; CANCER GRADING; CANCER SURVIVAL; CELL RENEWAL; CONTROLLED STUDY; DICER1 GENE; DISEASE ACTIVITY; GENE; GENE ACTIVATION; GENE AMPLIFICATION; GENE DUPLICATION; GENE INTERACTION; GENE LOCUS; GENE LOSS; GENE NUMBER; GENE OVEREXPRESSION; GENE TARGETING; GENE TRANSFER; GENETIC ASSOCIATION; GENETIC REGULATION; HMGA2 GENE; HUMAN; HUMAN CELL; LET7 GENE; LIN28 GENE; LIN28B GENE; MOLECULAR GENETICS; MYCN GENE; ONCOGENE MYC; OVARY CANCER; OVARY CELL; RNASEN GENE; SEROUS OVARIAN CANCER; STEM CELL; DOWN REGULATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; IMMUNOHISTOCHEMISTRY; OVARY TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BACTERIA (MICROORGANISMS);

DNA-BINDING PROTEINS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MICRORNAS; NUCLEAR PROTEINS; ONCOGENE PROTEINS; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79954618976     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018064     Document Type: Article

References (43)

1. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, et al. (2008) Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 5: e232.
2. Bookman MA, (2009) Trials with impact on clinical management: first line. Int J Gynecol Cancer 19 (Suppl 2): S55-62.
3. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, et al. (2008) Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451: 1111-1115.
4. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, et al. (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134.
5. Tothill RW, Tinker AV, George J, Brown R, Fox SB, et al. (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14: 5198-5208.
6. Boyerinas B, Park SM, Hau A, Murmann AE, Peter ME, (2009) The role of Let-7 in cell differentiation and cancer. Endocr Relat Cancer.
7. Roush S, Slack FJ, (2008) The let-7 family of microRNAs. Trends Cell Biol 18: 505-516.
8. Peter ME, (2009) Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle 8: 843-852.
9. Park SM, Shell S, Radjabi AR, Schickel R, Feig C, et al. (2007) Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle 6: 2585-2590.
10. Bartel DP, (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
11. Beilharz TH, Humphreys DT, Clancy JL, Thermann R, Martin DI, et al. (2009) microRNA-mediated messenger RNA deadenylation contributes to translational repression in mammalian cells. PLoS ONE 4: e6783.
12. Filipowicz W, Bhattacharyya SN, Sonenberg N, (2008) Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 9: 102-114.
13. Yu F, Yao H, Zhu P, Zhang X, Pan Q, et al. (2007) let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131: 1109-1123.
14. Shell S, Park SM, Radjabi AR, Schickel R, Kistner EO, et al. (2007) Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A 104: 11400-11405.
15. Nishino J, Kim I, Chada K, Morrison SJ, (2008) Hmga2 promotes neural stem cell self-renewal in young but not old mice by reducing p16Ink4a and p19Arf Expression. Cell 135: 227-239.
16. Cleynen I, Van de Ven WJ, (2008) The HMGA proteins: a myriad of functions (Review). Int J Oncol 32: 289-305.
17. Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, et al. (2009) Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 41: 843-848.
18. Malek A, Bakhidze E, Noske A, Sers C, Aigner A, et al. (2008) HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer 123: 348-356.
19. Chang TC, Zeitels LR, Hwang HW, Chivukula RR, Wentzel EA, et al. (2009) Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc Natl Acad Sci U S A.
20. Cotterman R, Knoepfler PS, (2009) N-Myc regulates expression of pluripotency genes in neuroblastoma including lif, klf2, klf4, and lin28b. PLoS ONE 4: e5799.
21. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, et al. (2006) Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 3: e47.
22. Murph MM, Liu W, Yu S, Lu Y, Hall H, et al. (2009) Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. PLoS ONE 4: e5583.
23. Etemadmoghadam D, deFazio A, Beroukhim R, Mermel C, George J, et al. (2009) Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res 15: 1417-1427.
24. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
25. Bonome T, Levine DA, Shih J, Randonovich M, Pise-Masison CA, et al. (2008) A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res 68: 5478-5486.
26. Friedman RC, Farh KK, Burge CB, Bartel DP, (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19: 92-105.
27. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, et al. (2008) Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 359: 2641-2650.
28. Jakymiw A, Patel RS, Deming N, Bhattacharyya I, Shah P, et al. (2010) Overexpression of dicer as a result of reduced let-7 MicroRNA levels contributes to increased cell proliferation of oral cancer cells. Genes Chromosomes Cancer 49: 549-559.
29. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, et al. (2008) Widespread changes in protein synthesis induced by microRNAs. Nature 455: 58-63.
30. Heo I, Joo C, Cho J, Ha M, Han J, et al. (2008) Lin28 mediates the terminal uridylation of let-7 precursor MicroRNA. Mol Cell 32: 276-284.
31. Newman MA, Thomson JM, Hammond SM, (2008) Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing. RNA 14: 1539-1549.
32. Rybak A, Fuchs H, Smirnova L, Brandt C, Pohl EE, et al. (2008) A feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during neural stem-cell commitment. Nat Cell Biol 10: 987-993.
33. Chen X, Xu H, Yuan P, Fang F, Huss M, et al. (2008) Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell 133: 1106-1117.
34. Tarca AL, Draghici S, Khatri P, Hassan SS, Mittal P, et al. (2009) A novel signaling pathway impact analysis. Bioinformatics 25: 75-82.
35. Schwab M, (2004) MYCN in neuronal tumours. Cancer Lett 204: 179-187.
36. Zitterbart K, Filkova H, Tomasikova L, Necesalova E, Zambo I, et al. (2010) Low-level copy number changes of MYC genes have a prognostic impact in medulloblastoma. J Neurooncol.
37. Mahajan A, Liu Z, Gellert L, Zou X, Yang G, et al. (2010) HMGA2: a biomarker significantly overexpressed in high-grade ovarian serous carcinoma. Mod Pathol 23: 673-681.
38. Peng S, Maihle NJ, Huang Y, (2010) Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer. Oncogene 29: 2153-2159.
39. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
40. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874.
41. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511.
42. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, et al. (2009) Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459: 717-721.
43. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, et al. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346: 1937-1947.